Abacus Medicine Pharma Services (AMPS) and AddMedica are proud to announce the signing of a partnership agreement for the marketing and distribution of Siklos® in Benelux.

Siklos® 100mg and 1000mg film-coated tablets are indicated for the treatment of adults, adolescents and children over two years of age who have sickle-cell syndrome. Siklos® is used to prevent recurrent, painful vaso-occlusive crises that happen when blood vessels become blocked by the abnormal red blood cells, restricting the flow of blood to an organ.

Simon Estcourt, Managing Director of Abacus Medicine Pharma Services explains:

“This partnership agreement between Abacus Medicine Pharma Services and AddMedica is a fantastic opportunity as it unlocks the potential of Siklos® in the Benelux countries. We are delighted that this distribution agreement will make this treatment option available to patients in Belgium, The Netherlands and Luxembourg.” 

Franck Hamalian, President of AddMedica continues: “AddMedica is very proud to join forces with Abacus Medicine Pharma Services to keep enhancing access to treatment for sickle-cell disease patients as well as the reach of Siklos® in important European countries.”

Approximately 17 million people across the world live with sickle-cell disease and 300,000 infants are born with the disease every year. The partnership agreement between Abacus Medicine Pharma Services and AddMedica is an important step in providing better access to medicine and better healthcare to patients with unmet needs, as the agreement ensures that Siklos® will be in stock in the Benelux countries.

Product information

The Netherlands

  • Siklos® film-coated tablets 60 pcs. 100mg (16938577)
  • Siklos® film-coated tablets 30 pcs. 1000mg (16939433)


  • Siklos® film-coated tablets 60 pcs. 100mg (0844169)


  • Siklos® film-coated tablets 60 pcs. 100mg (3422086)

Abacus Medicine Pharma Services is part of the Abacus Medicine Group, a fast-growing supplier of original prescription medicines. +1,200 employees service thousands of customers in Europe and the rest of the world. With a customised ERP system, a bespoke global distribution centre and a leadership team with decades of experience, AMPS is evolving into the next-generation healthcare and pharma services company by combining the infrastructure and skills at Abacus Medicine with the experience and expertise within AMPS.

AddMedica is a European company focused on developing and market medical products for rare diseases and niche markets. By developing, registering and/or market dedicated medical products in rare and debilitating diseases, the mission of AddMedica is to support physicians, patients, and managed care organizations with high medical value solutions. The company’s DNA is based on a flexible business model, including partnerships, specially adapted to the development, market and distribution of innovative and original products dedicated to rare and/or neglected diseases.

Company contacts

For communication queries regarding Abacus Medicine Pharma Services, please contact:

Andrew Waiton, Senior Marketing Consultant

Email: andrew.waiton@abacusmedicine.com

Phone: +44 7810 265 076

For ordering queries, please contact:  


For communications queries regarding AddMedica, please contact:

Anne-Sophie Degorce-Dumas, Marketing and Market Access Director

Email: anne-sophie.degorce-dumas@theravia.com

Phone: +33 (0)1 72 69 01 86